CDC25B and neoplasm: JQ1 as a single agent suppressed the growth of PA18 tumors for the duration of treatment (P < 0.0001), but only delayed PA16 tumor growth compared to controls [Figure 2A and B], Comparison of tumor volumes at completion of therapy (final tumor volume) showed a <1.5-fold difference between treated and control PA16 CDC25B-low tumors, and a >2.6-fold difference between treated and control PA18 CDC25B-high tumors (P < 0.001) [Figure 2A and B, right panels].